Off-label Prescription in Paediatric Dermatology: A Retrospective Observational Study in a Tertiary Hospital
DOI:
https://doi.org/10.2340/actadv.v102.11937Keywords:
child, dermatology, off-label use, pediatrics, prevalenceAbstract
Off-label prescription in paediatric patients is common, where some studies indicate that dermatological conditions are more prone to off-label treatment. This is the first study to analyse the prevalence of off-label prescription in paediatric dermatology consultation. This retrospective observational study was performed using the medical records of paediatric patients who were evaluated in a paediatric dermatological consultation in Pontevedra University Hospital, Pontevedra, Spain. Of the 468 patients reviewed, 186 prescriptions were issued and 51.10% were off-label prescription drugs. The dermatological conditions for which off-label prescription was most common were atopic dermatitis (29.0%), followed by warts (12.9%) and infantile haemangiomas (11.8%). With respect to drugs, topical tacrolimus (23.7%) was the most frequently prescribed off-label drug. The main reason for prescribing an off-label drug was for a disease not included on the label (62.4%), followed by issuing it at a lower age than authorized (55.9%). There was a significant association between a higher percentage of off-label prescription and younger age (p < 0.001), and the treatment of vitiligo, infantile haemangiomas and warts (p < 0.001). Likewise, the off-label prescription was significantly more common in the case of topical terbinafine, timolol, desloratadine and topical salicylic acid (p < 0.001). To conclude, off-label prescription is predominant in paediatric dermatology, as observed in 51.1% of our patients.
Downloads
References
Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol 2015; 79: 357-369.
https://doi.org/10.1111/bcp.12305 DOI: https://doi.org/10.1111/bcp.12305
Lass J, Irs A, Pisarev H, Leinemann T, Lusar I. Off label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf 2011; 20: 474-481.
https://doi.org/10.1002/pds.2125 DOI: https://doi.org/10.1002/pds.2125
Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L et al. Pediatric off-label drug use in China: risk factor and management strategies. J Evid Based Med 2013; 6: 4-18.
https://doi.org/10.1111/jebm.12017 DOI: https://doi.org/10.1111/jebm.12017
Schirm E, Tobi H, de Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003; 111: 291-295.
https://doi.org/10.1542/peds.111.2.291 DOI: https://doi.org/10.1542/peds.111.2.291
Parikh SA, David SA, Krowchuk DP, Feldman SR. Common use of prescription off-label acne therapy in children younger than 12 years old. Pediatr Dermatol 2014; 31: 551-555.
https://doi.org/10.1111/pde.12379 DOI: https://doi.org/10.1111/pde.12379
Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87: 982-990.
https://doi.org/10.1016/j.mayocp.2012.04.017 DOI: https://doi.org/10.1016/j.mayocp.2012.04.017
Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie 2018; 73: 135-149.
https://doi.org/10.1016/j.therap.2018.02.002 DOI: https://doi.org/10.1016/j.therap.2018.02.002
Gerlero P, Hernández-Martín Á. Treatment of warts in children: an update. Actas Dermosifiliogr 2016; 107: 551-558. DOI: https://doi.org/10.1016/j.adengl.2016.06.001
https://doi.org/10.1016/j.ad.2016.04.010 DOI: https://doi.org/10.1016/j.ad.2016.04.010
Muñoz-Garza FZ, Ríos M, Roé-Crespo E, Bernabeu-Wittel J, Montesarrat-García MT, Puig L et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage. JAMA Dermatol 2021; 157: 583-587.
https://doi.org/10.1001/jamadermatol.2021.0596 DOI: https://doi.org/10.1001/jamadermatol.2021.0596
Roohaninasab M, Mansouri P, Seirafianpour F, Naeini AJ, Goodarzi A. Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: a comprehensive review study. Dermatol Ther 2021; 34: e14550.
https://doi.org/10.1111/dth.14550 DOI: https://doi.org/10.1111/dth.14550
Mahé E, Corgibet F, Maccari F, Hadj-Rabia S, Phan C, Ruer-Mulard M et al. Off-label drugs in childhood psoriasis. Ann Dermatol Venereol 2020; 147: 429-438.
https://doi.org/10.1016/j.annder.2020.01.021 DOI: https://doi.org/10.1016/j.annder.2020.01.021
Blanco-Reina E, Vega-Jiménez MA, Ocaña-Riola R, Márquez-Romero EI, Bellido-Estévez I. Drug prescriptions study in the outpatient setting: assessment of off-label uses in children. Aten Primaria 2015; 47: 344-350.
https://doi.org/10.1016/j.aprim.2014.07.010 DOI: https://doi.org/10.1016/j.aprim.2014.07.010
Ellul IC, Grech V, Attard-Montalto S. Paediatric off-label and unlicensed prescribing in primary care in Malta: prospective observational drug utilisation study. Int J Risk Saf Med 2015; 27: 123-134.
https://doi.org/10.3233/JRS-150654 DOI: https://doi.org/10.3233/JRS-150654
Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009; 9: 81-88.
https://doi.org/10.1016/j.acap.2008.11.010 DOI: https://doi.org/10.1016/j.acap.2008.11.010
Published
How to Cite
License
Copyright (c) 2023 Carmen Couselo-Rodríguez, Ana Batalla, Sandra Martínez-Fernández, Carmela Dávila-Pousa, Diego Soto-García, Lucía Vilanova-Trillo, Ángeles Flórez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
